Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy

Simple item page
dc.contributor.authorChowdhury, Rajdeep
dc.contributor.authorRoy, Aniruddha
dc.date.accessioned2024-01-11T06:31:28Z
dc.date.available2024-01-11T06:31:28Z
dc.date.issued2020-07
dc.description.abstractRecent studies have demonstrated that autophagy plays a critical role in reducing the drug sensitivity of docetaxel (DTX) therapy. Disulfiram (DSF) has exhibited potent autophagy inducing activity in multiple studies. We hypothesized that DSF co-treatment could sensitize breast cancer cells to DTX therapy via autophagy modulation.en_US
dc.identifier.urihttps://link.springer.com/article/10.1007/s43440-020-00122-1
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13807
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.subjectPharmacyen_US
dc.subjectDisulfiramen_US
dc.subjectBreast canceren_US
dc.subjectAutophagyen_US
dc.titleDisulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagyen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Department of Pharmacy